68Ga-satoreotide trizoxetan is a novel somatostatin receptor antagonist associated with high
sensitivity and reproducibility in neuroendocrine tumor (NET) detection and localization …

Preclinical and preliminary clinical evidence indicates that radiolabeled somatostatin (sst)
receptor antagonists perform better than agonists in detecting neuroendocrine tumors …

Radiolabeled somatostatin receptor (sst) agonists are integral to the diagnosis of
gastroenteropancreatic neuroendocrine tumors (GEP-NETs), but detection rates, especially …

Radiolabeled somatostatin (sst) receptor agonists are integral to the diagnosis of
gastroenteropancreatic neuroendocrine tumors (NETs), but detection rates, especially of …

266 Objectives To present the first clinical data on 68 Ga-OPS202, a radiolabeled
somatostatin (sst) receptor antagonist, for PET/CT imaging of gastroenteropancreatic …

Purpose: Abundant expression of somatostatin receptors (sst) is a characteristic of
neuroendocrine tumors (NET). Thus, radiolabeled somatostatin analogs have emerged as …

Purpose We present the results of an open-label, phase I/II study evaluating the safety and
efficacy of the novel somatostatin receptor (SSTR) antagonist [177Lu] Lu-satoreotide …

Somatostatin receptor PET tracers such as [68Ga-DOTA, 1-Nal3]-octreotide (68Ga-
DOTANOC) and [68Ga-DOTA, Tyr3]-octreotate (68Ga-DOTATATE) have shown promising …

Purpose To evaluate the dosimetry and pharmacokinetics of the novel radiolabelled
somatostatin receptor antagonist [177Lu] Lu-satoreotide tetraxetan in patients with …

ABSTRACT Background 68 Ga-DOTA0-Tyr3-octreotide (68 Ga-DOTATOC) positron
emission tomography–CT (PET-CT) has superior diagnostic performance compared to the …